Hepatology News

The CDC published a guide that hospitals can use to reduce the risk for burnout among health care staff.

A “significantly greater” percentage of patients with primary biliary cholangitis achieved biochemical response, alkaline phosphatase normalization and reduction in pruritis when treated with seladelpar vs. placebo, according to a study.

Madrigal Pharmaceutical’s Rezdiffra received accelerated FDA approval for the treatment of patients with metabolic dysfunction-associated steatohepatitis with moderate-to-advanced fibrosis, according to a company release.

The FDA has approved Mirum Pharmaceuticals’ Livmarli oral solution for treatment of cholestatic pruritus in patients aged 5 years and older with progressive familial intrahepatic cholestasis, according to a company release.

As we discussed in our overview of the private equity, or PE, physician practice model, the buyer in an acquisition is often a PE-sponsored management services organization that purchases the nonclinical aspects of the practice’s business.

Completing medical education and training is a monumental achievement that can launch a successful lifetime career.

Sodium-glucose cotransporter 2 inhibitors were associated with a higher likelihood of disease regression among patients with concomitant metabolic dysfunction-associated steatotic liver disease and type 2 diabetes, data showed.

Non-alcoholic fatty liver disease is an independent risk factor for osteoarthritis, according to data published in Arthritis Research & Therapy.

A “rapid response to hepatitis A exposure” helped minimize the risk for transmission and prevent an HAV outbreak among incarcerated persons in a Los Angeles County jail, according to an investigation in Morbidity and Mortality Weekly Report.

DENVER — A low weekly dose of semaglutide can safely minimize what used to be called nonalcoholic fatty liver disease in people with HIV, a first-of-its-kind study found.